Outcome of Board Meeting

November 05, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 64/26-27 Our Reference No. 64/26-27 Dear Sir/ Madam, Sub: Outcome of Board Meeting for the quarter and half year ended September 30, 2026 - SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform that the Board at its meeting held today, i.e. November 05, 2026 has approved the following: A. Financial Results 1. The Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026; and 2. Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026. The meeting commenced at 1:15 p.m. and concluded at 4:15 p.m. You are requested to take the same on records. Thanking You. Yours faithfully, Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E:complianceofficer@glenmarkpharma.com GlenmaQk A new way for a new world Glenmark Pharmaceuticals Limited Statement of Unaudited flnancial results for the quarter and half year ended 30 September 2026 (All amounts in million of Indian Rupees unless otherwise stated) Standalone Particular• Quart.er ended Quarter eaded Quarter ended Half year ended Hall year ended Year eaded 30/09/2026 30/06/2026 30/09/2025 30/09/2026 30/09/2025 31/03/2026 ,Unaudltedl (Unaudited) (Ull.auditedJ (Ua.audltedJ ,Unaudited) (Audited) I Revenue from operations (a) Net sales 23,753.73 23,425.26 12,195.32 47,178.99 33,984.28 79,342.23 (b) Other operating income 1,004.47 924.67 3,191.28 1,929.14 5,351.60 5,058.76 Total revenue from operations 24,758.20 24,349.93 15,386.60 49,108.13 39,335.88 84,400.99 II Other income 1,081.93 1,154.11 2,857.56 2,236.04 3,550.91 7,720.23 JJI Total income ( J + II } 25,840.13 25,504.04 18,244.16 51,344.17 42,886.79 92,121.22 IV Expenses {a) Cost of materials consumed 7,568.92 6,279.86 6,678.20 13,848.78 13,450.60 27,755.75 {b) Purchases of stock-in-trade 1,236.40 1,414.36 913.13 2,650.76 1,906.38 4,087.95 (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (538.38) 491.60 (1,028.50) (46.78) (1,612.60) (1,054.15) (d) Employee benefits expense 4,497.66 4,540.81 4,536.75 9,038.47 8,621.18 17,904.10 (e) Finance costs 309.34 232.45 233.96 541.79 388.54 787.45 {f) Depreciation, amortisation and impairment expense 629.97 623.17 589.34 1,253.14 1,165.73 2,358.89 (g) Other expenses 5,175.60 5,490.77 6,067.00 10,666.37 11,468.71 24,933.36 Total expenses (lV) 18,879.51 19,073.02 17,989.88 37,952.53 35,388.54 76,773.35 V Profit/ (loss) before exceptional items and tax ( III -IV ) 6,960.62 6,431.02 254.28 13,391.64 7,498.25 15,347.87 Vl Exceptional items (gain)/ loss (Refer note 5) 1,429.25 (2,230.00) 9,317.94 (800.75) 12,550.26 18,008.58 VII Profit/ (Joss) before tax (V -VI) 5,531.37 8,661.02 (9,063.66) 14,192.39 (5,052.01) (2,660.71) VJJI Tax expense [charge / (credit)I : Current tax 1,037.47 1,128.41 (701.72) 2,165.88 Deferred tax 144.96 176.24 (970.05) 321.20 (962.38) (652.72) IX Profit/(loss) after tax for the period / year (VII -VIII) 4,348.94 7,356.37 (7,391.89) 11,705.31 (4,089.63) (2,007.99) X Profit/ (loss) for the period / year attributable to: -Non-controlling interests -Owners of the parent 4,348.94 7,356.37 (7,391.89) 11,705.31 (4,089.63) (2,007.99) XI Other comprehensive income / {loss) A (i) Items that will not be reclassified to profit or loss (172.58) 8.10 (171.02) (164.48) (179.22) (159.85) {ii) Income tax relating to items that will not be reclassified to profit or loss 20.71 (2.04) 24.82 18.67 27.68 (9.71) B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Total other comprehensive income/(loss) for the period/ year (151.87) 6.06 (146.20) (145.81) (151.54) (169.56) XII Total comprehensive income for the period/ year (IX+Xl) 4,197.07 7,362.43 (7,538.09) 11,559.50 (4,241.17) (2,177.55) XJJI Total comprehensive income attributable to: -Non-controlling interests -Owners of the parent 4,197.07 7,362.43 (7,538.09) 11,559.50 (4,241.17) (2,177.55) XIV Paid up Equity Share Capital, Equity Shares of Re. 1 /-each 282.22 282.20 282.20 282.22 282.20 282.20 xv Other equity (other than revaluation reserve) 2,41,221.04 XVI Earnings per share (EPS) (not annualised except for the year ended 31 March) Basic (in Rupees ) 15.41 26.07 (26.19) 41.48 (14.49) (7.12) Diluted (in Rupees ) 15.41 26.06 (26.19) 41.47 (14.49) (7.12) /;f:: " Glenmark Pharmaceuticals Limited . . . ~ ('I~ ~ ~ MAc~ =@ienm~H~B:D:-5aw:mt-"Marg;"-Alfdlmt1tE:m-}, Mrrmbru·400·099;--Inrlilf. . ~,-i- · l<" ~ ~I~\ T: +91224018 9999 F: 91 22 4018 9986 CIN No.: L242~9M~1977PLC0199~2 W: www. *fua~~fil.tna.ffP} . ll; a.I Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026 E: ¢<"il_} ~~, 1a nceoffi<~y., -:,-~l,n er, Acco..::,-;;. ).9 * ,(:)',, c;lenma~k A new way for a new world Glenmark Pharmaceuticals Limited Statement of Unaudited financial results for the quarter and half year ended 30 September 2026 (All amounts in million of Indian Rupees, unless otherwise stated) Consolidated Particulars Quarter ended Quarter esaded Quarter eu.ded Half year ended Half year eaded Year ended 30/09/2026 30/06/2026 30/09/2025 30/09/2026 30/09/2025 31/03/2026 (Vo.audited) (Unaudited I (Unaudited) (Unauditedl (Unaudited) (Audited.I I Revenue from operations (a) Net sales 41,570.91 39,317.30 60,037.94 80,888.21 90,631.27 1,67,114.03 (b) Other operating income 902.37 867.53 430.76 1,769.90 2,481.83 2,711.08 Total revenue from operations 42,473.28 40,184.83 60,468.70 82,658.11 93,113.10 1,69,825.11 II Other income 25.41 657.64 2,006.29 683.05 2,270.71 4,606.19 III Total income { I + II ) 42,498.69 40,842.47 62,474.99 83,341.16 95,383.81 1,74,431.30 IV Expenses (a) Cost of materials consumed 8,378.80 6,010.66 7,225.00 14,389.46 14,549.68 29,614.59 (b) Purchases of stock-in-trade 5,298.39 6,607.53 6,204.46 11,905.92 12,017.87 23,966.43 (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (621.85} (160.20) (784.41) (782.05) (3,766.74) (6,106.39) (d) Employee benefits expense 10,276.44 9,346.95 10,862.59 19,623.39 18,490.13 35,778.53 (e) Finance costs 637.67 539.97 664.63 1,177.64 1,246.89 2,087.25 (f} Depreciation, amortisation and impairment expense 1,804.16 1,731.74 1,412.00 3,535.90 2,711.26 5,734.81 (g) Other expenses 10,503.45 10,331.93 13,365.55 20,835.38 22,421.45 40,847.78 Total expenses (IV) 36,277.06 34,408.58 38,949.82 70,685.64 67,670.54 1,31,923.00 V Profit/ (loss) before exceptional items and tax ( III -N ) 6,221.63 6,433.89 23,525.17 12,655.52 27,713.27 42,508.30 VI Exceptional items (gain)/ loss (Refer note 5) 2,838.75 13,851.16 2,838.75 17,083.48 22,660.84 VII Profit/(loss} before tax (V -VI) 3,382.88 6,433.89 9,674.01 9,816.77 10,629.79 19,847.46 VIII Tax expense (charge / (credit)I : Current tax 1,279.93 2,108.17 4,600.25 3,388.10 5,693.36 6,764.86 Deferred tax (535.35) (502.56} (1,030.56} (1,037.91) (1,637.62} (536.92} IX Profit/(loss} after tax for the period / year ( VII -VIII} 2,638.30 4,828.28 6,104.32 7,466.58 6,574.05 13,619.52 X Profit/ (loss} for the period / year attributable to: -Non-controlling interests 0.47 (0.96 [Showing first 8,000 characters — download PDF for full document]